TABLE OF CONTENTS
Volume 17, Issue 2 (February 2003)
Spotlight on IMATINIB as a Model for Signal Transduction Inhibitors |
Original Manuscripts |
Spotlight Correspondence |
Correspondence |
Comments on a Published Papers |
Book Review
Review
A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases FREE
H Hasle, C M Niemeyer, J M Chessells, I Baumann, J M Bennett, G Kerndrup and D R Head
Leukemia 17: 277-282; doi:10.1038/sj.leu.2402765
Spotlight on IMATINIB as a Model for Signal Transduction Inhibitors
The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains FREE
M Stanglmaier, M Warmuth, I Kleinlein, S Reis and M Hallek
Leukemia 17: 283-289; doi:10.1038/sj.leu.2402778
Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias FREE
A Shimoni, N Kröger, A R Zander, J M Rowe, I Hardan, A Avigdor, M Yeshurun, I Ben-Bassat and A Nagler
Leukemia 17: 290-297; doi:10.1038/sj.leu.2402808
Effect of imatinib on haematopoietic recovery following idarubicin exposure FREE
H Ruchatz, M Puttini, L Cleris, S Pilotti, C Gambacorti-Passerini and F Formelli
Leukemia 17: 298-304; doi:10.1038/sj.leu.2402800
Original Manuscripts
Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome FREE
J-H Lee, J-H Lee, Y-R Shin, J-S Lee, W-K Kim, H-S Chi, C-J Park, E-J Seo and K-H Lee
Leukemia 17: 305-313; doi:10.1038/sj.leu.2402798
Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195 FREE
E Feldman, M Kalaycio, G Weiner, S Frankel, P Schulman, L Schwartzberg, J Jurcic, E Velez-Garcia, K Seiter, D Scheinberg, D Levitt and N Wedel
Leukemia 17: 314-318; doi:10.1038/sj.leu.2402803
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts FREE
V Ribrag, F Suzan, C Ravoet, W Feremans, A Guerci, F Dreyfus, G Damaj, J M Vantelon, J H Bourhis and P Fenaux
Leukemia 17: 319-322; doi:10.1038/sj.leu.2402726
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211 FREE
J C Byrd, B Peterson, L Piro, A Saven, J W Vardiman, R A Larson and C Schiffer
Leukemia 17: 323-327; doi:10.1038/sj.leu.2402752
Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up FREE
S Yetgin, M A Tuncer, M Çetin, F Gümrük, I Yenicesu, B Tunç, A F Öner, H Toksoy, A Koç, D Aslan, E Özyürek, L Olcay, L Atahan, E Tunçbilek and A Gürgey
Leukemia 17: 328-333; doi:10.1038/sj.leu.2402673
Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins FREE
L Herrera, S Yarbrough, V Ghetie, D B Aquino and E S Vitetta
Leukemia 17: 334-338; doi:10.1038/sj.leu.2402790
Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial FREE
S de Botton, S Chevret, V Coiteux, H Dombret, M Sanz, J San Miguel, D Caillot, A Vekhoff, M Gardembas, A Stamatoulas, E Conde, A Guerci, C Gardin, M Fey, D Cony Makhoul, O Reman, J de la Serna, F Lefrere, C Chomienne, L Degos and P Fenaux for the European APL group
Leukemia 17: 339-342; doi:10.1038/sj.leu.2402807
The emergence of a C/EBP
mutation in the clonal evolution of MDS towards secondary AML FREE
A Kaeferstein, U Krug, J Tiesmeier, M Aivado, M Faulhaber, M Stadler, J Krauter, U Germing, W K Hofmann, H P Koeffler, A Ganser and W Verbeek
Leukemia 17: 343-349; doi:10.1038/sj.leu.2402805
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells FREE
M I Klisovic, E A Maghraby, M R Parthun, M Guimond, A R Sklenar, S P Whitman, K K Chan, T Murphy, J Anon, K J Archer, L J Rush, C Plass, M R Grever, J C Byrd and G Marcucci
Leukemia 17: 350-358; doi:10.1038/sj.leu.2402776
Transcriptional activation is a key function encoded by MLL fusion partners FREE
B B Zeisig, S Schreiner, M-P García-Cuéllar and R K Slany
Leukemia 17: 359-365; doi:10.1038/sj.leu.2402804
The protein tyrosine phosphatase HePTP regulates nuclear translocation of ERK2 and can modulate megakaryocytic differentiation of K562 cells FREE
S M Pettiford and R Herbst
Leukemia 17: 366-378; doi:10.1038/sj.leu.2402767
Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-
B activation and cFLIPL up-regulation FREE
R Bortul, P L Tazzari, A Cappellini, G Tabellini, A M Billi, R Bareggi, L Manzoli, L Cocco and A M Martelli
Leukemia 17: 379-389; doi:10.1038/sj.leu.2402793
Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-XLand XIAP in the prolonged survival of monocytic cells FREE
M B Miranda, K F Dyer, J R Grandis and D E Johnson
Leukemia 17: 390-400; doi:10.1038/sj.leu.2402779
Telomere dynamics in childhood leukemia and solid tumors: a follow-up study FREE
S Franco, M F Ozkaynak, C Sandoval, O Tugal, S Jayabose, M Engelhardt and M A S Moore
Leukemia 17: 401-410; doi:10.1038/sj.leu.2402815
Microsatellite instability and hMLH1 promoter hypermethylation in Richter's transformation of chronic lymphocytic leukemia FREE
Z Fülöp, B Csernus, B Tímár, Á Szepesi and A Matolcsy
Leukemia 17: 411-415; doi:10.1038/sj.leu.2402792
False leukemia–lymphoma cell lines: an update on over 500 cell lines FREE
H G Drexler, W G Dirks, Y Matsuo and R A F MacLeod
Leukemia 17: 416-426; doi:10.1038/sj.leu.2402799
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma FREE
C S Debes-Marun, G W Dewald, S Bryant, E Picken, R Santana-Dávila, N González-Paz, J M Winkler, R A Kyle, M A Gertz, T E Witzig, A Dispenzieri, M Q Lacy, S V Rajkumar, J A Lust, P R Greipp and R Fonseca
Leukemia 17: 427-436; doi:10.1038/sj.leu.2402797
Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy FREE
F Prósper, C Solá, J Hornedo, C Arbona, P Menéndez, A Orfao, A Lluch, H Cortés-Funes, J J López and J García-Conde
Leukemia 17: 437-441; doi:10.1038/sj.leu.2402750
IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells FREE
M C Levesque, M A Misukonis, C W O'Loughlin, Y Chen, B E Beasley, D L Wilson, D J Adams, R Silber and J B Weinberg
Leukemia 17: 442-450; doi:10.1038/sj.leu.2402783
The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells FREE
S C E Bolick, T H Landowski, D Boulware, M M Oshiro, J Ohkanda, A D Hamilton, S M Sebti and W S Dalton
Leukemia 17: 451-457; doi:10.1038/sj.leu.2402832
Spotlight Correspondence
Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation FREE
P Vandenberghe, N Boeckx, E Ronsyn, R Decorte, G Verhoef and A Hagemeijer
Leukemia 17: 458-460; doi:10.1038/sj.leu.2402811
Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate FREE
C Schoch, T Haferlach, W Kern, S Schnittger, U Berger, R Hehlmann, W Hiddemann and A Hochhaus
Leukemia 17: 461-463; doi:10.1038/sj.leu.2402813
Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome FREE
M W Drummond, C J Lush, M A Vickers, F M Reid, J Kaeda and T L Holyoake
Leukemia 17: 463-465; doi:10.1038/sj.leu.2402814
Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib FREE
P Meeus, H Demuynck, Ph Martiat, L Michaux, E Wouters and A Hagemeijer
Leukemia 17: 465-467; doi:10.1038/sj.leu.2402791
Correspondence
Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin FREE
ChM Zwaan, D Reinhardt, H Jürgens, D R Huismans, K Hählen, O P Smith, A Biondi, E R van Wering, J Feingold and G J L Kaspers
Leukemia 17: 468-470; doi:10.1038/sj.leu.2402749
Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML FREE
D Steinbach, S Furchtbar, W Sell, J Lengemann, J Hermann, F Zintl and A Sauerbrey
Leukemia 17: 470-471; doi:10.1038/sj.leu.2402806
C-Kit point mutations in core binding factor leukemias: correlation with white blood cell count and the white blood cell index FREE
R Cairoli, G Grillo, A Beghini, A Tedeschi, C B Ripamonti, L Larizza and E Morra
Leukemia 17: 471-472; doi:10.1038/sj.leu.2402795
Deletion of the 5' abl region in Philadelphia chromosome-positive chronic myeloid leukemia FREE
F Morel, C Ka, M-J Le Bris, A Herry, P Morice, P Bourquard, J F Abgrall, C Berthou and M De Braekeleer
Leukemia 17: 473-474; doi:10.1038/sj.leu.2402816
Engraftment of allogeneic mesenchymal stem cells in the bone marrow of a patient with severe idiopathic aplastic anemia improves stroma FREE
L Fouillard, M Bensidhoum, D Bories, H Bonte, M Lopez, A-M Moseley, A Smith, S Lesage, F Beaujean, D Thierry, P Gourmelon, A Najman and N-C Gorin
Leukemia 17: 474-476; doi:10.1038/sj.leu.2402786
Comments on a Published Papers
Frequency of ETV6/AML1 fusion in adult acute lymphoblastic leukemia FREE
A Cuneo, P Agostini, A Vitale, R Foà and G Castoldi
Leukemia 17: 476-477; doi:10.1038/sj.leu.2402801
Response to Cuneo et al FREE
A V Moorman, M Martineau and C J Harrison
Leukemia 17: 477; doi:10.1038/sj.leu.2402802